Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00134251
Status:
COMPLETED
Last Update Posted:
2009-01-30
First Post:
2005-08-22
Brief Title:
Ascending Dose TolerabilitySafety of SLV308 for the Treatment of Parkinsons Disease
Sponsor:
Solvay Pharmaceuticals
Organization:
Solvay Pharmaceuticals
Study Overview
Official Title:
A Multicenter Randomized Double-Blind Placebo-Controlled Ascending Dose Parallel Group Study Exploring Effects of SLV308 up to 42 mgDay Administered as an Adjunctive Therapy to L-Dopa in Patients With Advanced Stage Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2009-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a multicenter randomized double-blind placebo controlled parallel group study of a seven-week ascending dose period of SLV308 adjunctive to L-dopa treatment in patients with advanced stage Parkinsons disease PD and dose-dependent motor fluctuations Patients outpatients will be randomized to one of three different treatment arms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EuDract no 2005-002432-10 | None | None | None |